These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 19748159

  • 1. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
    Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM.
    Neurobiol Aging; 2011 Aug; 32(8):1372-8. PubMed ID: 19748159
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
    Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE.
    Neurology; 2020 Oct 27; 95(17):e2378-e2388. PubMed ID: 32788242
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 7. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 8. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X, Dong C, Levin B, Crocco E, Loewenstein D, Zetterberg H, Blennow K, Wright CB, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2016 Nov 29; 12(11):1159-1166. PubMed ID: 27321472
    [Abstract] [Full Text] [Related]

  • 9. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.
    Alzheimers Res Ther; 2017 Oct 23; 9(1):87. PubMed ID: 29061195
    [Abstract] [Full Text] [Related]

  • 10. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM.
    J Alzheimers Dis; 2009 Oct 23; 16(3):601-7. PubMed ID: 19276554
    [Abstract] [Full Text] [Related]

  • 11. Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.
    Wang HY, Trocmé-Thibierge C, Stucky A, Shah SM, Kvasic J, Khan A, Morain P, Guignot I, Bouguen E, Deschet K, Pueyo M, Mocaer E, Ousset PJ, Vellas B, Kiyasova V.
    Alzheimers Res Ther; 2017 Jul 27; 9(1):54. PubMed ID: 28750690
    [Abstract] [Full Text] [Related]

  • 12. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.
    J Alzheimers Dis; 2012 Jul 27; 29(2):319-27. PubMed ID: 22233766
    [Abstract] [Full Text] [Related]

  • 13. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM.
    Alzheimers Res Ther; 2022 Aug 24; 14(1):115. PubMed ID: 36002891
    [Abstract] [Full Text] [Related]

  • 14. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T.
    Neurobiol Aging; 2007 Apr 24; 28(4):507-14. PubMed ID: 16546302
    [Abstract] [Full Text] [Related]

  • 15. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.
    J Alzheimers Dis; 2013 Apr 24; 36(2):401-8. PubMed ID: 23609762
    [Abstract] [Full Text] [Related]

  • 16. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S, Zhang J, Pan T, for Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2018 Oct 15; 685():109-113. PubMed ID: 30144541
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
    van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM.
    Alzheimers Dement; 2013 Sep 15; 9(5):481-7. PubMed ID: 23232269
    [Abstract] [Full Text] [Related]

  • 18. Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
    Lodeiro M, Ibáñez C, Cifuentes A, Simó C, Cedazo-Mínguez Á.
    J Alzheimers Dis; 2014 Sep 15; 41(1):223-32. PubMed ID: 24595197
    [Abstract] [Full Text] [Related]

  • 19. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH, Kim SH, Park SH, Kang SH, Choo IH, Alzheimer's Disease Neuroimaging Initiative.
    J Korean Med Sci; 2016 Feb 15; 31(2):286-95. PubMed ID: 26839485
    [Abstract] [Full Text] [Related]

  • 20. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Feb 15; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.